About pharming group nv - PHAR
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.
PHAR At a Glance
Pharming Group NV
Vondellaan 47
Leiden, Zuid-Holland 2332 AA
| Phone | 31-71-524-74-00 | Revenue | 377.30M | |
| Industry | Pharmaceuticals: Major | Net Income | 2.86M | |
| Sector | Health Technology | 2025 Sales Growth | 27.175% | |
| Fiscal Year-end | 12 / 2026 | Employees | N/A | |
| View SEC Filings |
PHAR Valuation
| P/E Current | 76.56 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 425.783 |
| Price to Sales Ratio | 3.498 |
| Price to Book Ratio | 4.474 |
| Price to Cash Flow Ratio | 26.50 |
| Enterprise Value to EBITDA | 39.605 |
| Enterprise Value to Sales | 3.328 |
| Total Debt to Enterprise Value | 0.092 |
PHAR Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 7.789 |
| Total Asset Turnover | 0.819 |
PHAR Liquidity
| Current Ratio | 2.586 |
| Quick Ratio | 2.026 |
| Cash Ratio | 1.553 |
PHAR Profitability
| Gross Margin | 85.052 |
| Operating Margin | 5.551 |
| Pretax Margin | 3.25 |
| Net Margin | 0.758 |
| Return on Assets | 0.62 |
| Return on Equity | 1.148 |
| Return on Total Capital | 0.728 |
| Return on Invested Capital | 0.805 |
PHAR Capital Structure
| Total Debt to Total Equity | 41.781 |
| Total Debt to Total Capital | 29.469 |
| Total Debt to Total Assets | 22.681 |
| Long-Term Debt to Equity | 38.639 |
| Long-Term Debt to Total Capital | 27.253 |